Exact Mass: 400.31298400000003
Exact Mass Matches: 400.31298400000003
Found 500 metabolites which its exact mass value is equals to given mass value 400.31298400000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Testosterone enanthate
testosterone enanthate is used in androgen substitution to replace testosterone at levels as close to physiological levels as is possible. For some androgen-dependent functions testosterone is a pro-hormone, peripherally converted to 5alpha-dihydrotestosterone (DHT) and 17beta-estradiol (E2), of which the levels preferably should be within normal physiological ranges. Furthermore, androgens should have a good safety profile without adverse effects on the prostate, serum lipids, liver or respiratory function, and they must be convenient to use and patient-friendly, with a relative independence from medical services. Natural testosterone is viewed as the best androgen for substitution in hypogonadal men. testosterone enanthate is used to treat male hypogonadism. Male hypogonadism is one of the most common endocrinologic syndromes. The diagnosis is based on clinical signs and symptoms plus laboratory confirmation via the measurement of low morning testosterone levels on two different occasions. Serum luteinizing hormone and follicle-stimulating hormone levels distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. In primary hypogonadal men the on bone mineral density (BMD) responds dose dependently to testosterone substitution, whereas in secondary hypogonadism only testosterone enanthate treatment significantly increased the BMD. In all mammalian species studied to date, testosterone has been found to be the predominant intratesticular steroid. In volunteers receiving hormonal contraception by using a combination of testosterone enanthate and levonorgestrel, there is a profound reduction of both intratesticular testosterone concentration and androgen bioactivity. High doses of testosterone enanthate can normalize hematocrit values of maintenance hemodialysis patients with replenished bone marrow iron stores. testosterone enanthate is classified as a prohibited substance by the World Anti-Doping Agency (WADA) and its use may be detected by way of the urinary testosterone/epitestosterone (T/E) ratio. (PMID: 16185098, 16467270, 15329035, 17530941, 17484401, 4028529, 12792150) [HMDB] Testosterone enanthate is used in androgen substitution to replace testosterone at levels as close to physiological levels as is possible. For some androgen-dependent functions testosterone is a pro-hormone, peripherally converted to 5alpha-dihydrotestosterone (DHT) and 17beta-estradiol (E2), of which the levels preferably should be within normal physiological ranges. Furthermore, androgens should have a good safety profile without adverse effects on the prostate, serum lipids, liver or respiratory function, and they must be convenient to use and patient-friendly, with a relative independence from medical services. Natural testosterone is viewed as the best androgen for substitution in hypogonadal men. testosterone enanthate is used to treat male hypogonadism. Male hypogonadism is one of the most common endocrinologic syndromes. The diagnosis is based on clinical signs and symptoms plus laboratory confirmation via the measurement of low morning testosterone levels on two different occasions. Serum luteinizing hormone and follicle-stimulating hormone levels distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. In primary hypogonadal men the on bone mineral density (BMD) responds dose dependently to testosterone substitution, whereas in secondary hypogonadism only testosterone enanthate treatment significantly increased the BMD. In all mammalian species studied to date, testosterone has been found to be the predominant intratesticular steroid. In volunteers receiving hormonal contraception by using a combination of testosterone enanthate and levonorgestrel, there is a profound reduction of both intratesticular testosterone concentration and androgen bioactivity. High doses of testosterone enanthate can normalize hematocrit values of maintenance hemodialysis patients with replenished bone marrow iron stores. testosterone enanthate is classified as a prohibited substance by the World Anti-Doping Agency (WADA) and its use may be detected by way of the urinary testosterone/epitestosterone (T/E) ratio. (PMID: 16185098, 16467270, 15329035, 17530941, 17484401, 4028529, 12792150). D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D000728 - Androgens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
Calcidiol
Calfcifediol is a prehormone that is produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) by the enzyme cholecalciferol 25-hydroxylase. Calcifediol is then converted in the kidneys into calcitriol (1,25-(OH)2D3), a secosteroid hormone that is the active form of vitamin D. It can also be converted into 24-hydroxycalcidiol in the kidneys via 24-hydroxylation. [Wikipedia]. 25-Hydroxycholecalciferol is found in many foods, some of which are green zucchini, green bell pepper, red bell pepper, and other animal fat. The major circulating metabolite of vitamin D3 (calciferon). It is produced in the liver and is the best indicator of the bodys vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. A - Alimentary tract and metabolism > A11 - Vitamins > A11C - Vitamin a and d, incl. combinations of the two > A11CC - Vitamin d and analogues H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D050071 - Bone Density Conservation Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
DG(10:0/10:0/0:0)
DG(10:0/10:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(10:0/10:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
7a-Hydroxy-cholestene-3-one
7a-Hydroxy-cholestene-3-one is a metabolite in bile acid synthesis. It is derived from 7a-hydroxy-cholesterol and can be further metabolized to 7a,12a,-dihydroxy-cholest-4-en-3-one. Analysis of 7a-Hydroxycholestene-3-one (HCO) in serum may serve as a novel, simple, and sensitive method for the detection of bile acid malabsorption in patients with chronic diarrhea of unknown origin (PMID 9952217) [HMDB] 7a-Hydroxy-cholestene-3-one is a metabolite in bile acid synthesis. It is derived from 7a-hydroxy-cholesterol and can be further metabolized to 7a,12a,-dihydroxy-cholest-4-en-3-one. Analysis of 7a-Hydroxycholestene-3-one (HCO) in serum may serve as a novel, simple, and sensitive method for the detection of bile acid malabsorption in patients with chronic diarrhea of unknown origin (PMID 9952217).
diapolycopene
Gefarnate
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
17beta-Hydroxy-5alpha-androstan-3-one cyclohexanecarboxylate
7-Ketocholesterol
7-Ketocholesterol is a major oxidation product of cholesterol (oxysterol) found in human atherosclerotic plaque and is more atherogenic than cholesterol in some animal studies. Oxysterols (oxygenated forms of cholesterol) are present at low levels in the circulation and accumulate is plasma and tissues in some pathologies. In atherosclerotic lesions, 7-oxygenated oxysterols, predominantly 7-ketocholesterol, accumulate and have been implicated in the pathology of the disease. There is some in vivo and in vitro evidence that sterol 27-hydroxylase acts on 7-ketocholesterol to initiate its degradation to more polar, water-soluble products. Recent studies indicate an alternative mechanism, in which 7-ketocholesterol is reduced to 7 beta-hydroxycholesterol by 11 beta-hydroxysteroid dehydrogenase type 1. 7-Ketocholesterol can inhibit cholesterol 7 alpha-hydroxylase, the rate-limiting step in bile acid biosynthesis, as well as strongly inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It has even been suggested that 7-ketocholesterol is formed enzymically as an endogenous regulator of cholesterol biosynthesis. However, when tested as a pharmacological cholesterol-lowering agent, inhibition of HMG-CoA reductase was rapidly overcome and the 7-ketocholesterol metabolised. In vitro, 7-ketocholesterol has wide-ranging and potent effects, most of which have the potential to contribute to atherosclerosis. For example, 7-ketocholesterol can be cytotoxic and can induce apoptosis in vascular cells. These effects, either individually or more likely, in combination, all implicate 7-ketocholesterol in the initiation and development of atherosclerosis, but further work is needed to establish whether or not its role is a direct causal one. 7-Ketocholesterol is the second most abundant oxysterol found in human atherosclerotic plaque, after the enzymically formed 27-hydroxycholesterol (cholest-5-ene-3beta,27-diol). 7-Ketocholesterol differs from cholesterol by a ketone functional group present at the 7-position. It is produced from cholesterol via the epimeric cholesterol 7-hydroperoxides (cholest-5-ene-3beta-ol-7-hydroperoxide) which decompose to the epimeric 7-hydroxycholesterols (cholest-5-ene-3beta,7-diol) and 7-ketocholesterol. 7-Ketocholesterol is a major dietary oxysterol. It has also been widely suggested that 7-ketocholesterol present in atherosclerotic tissue may be derived from the diet. Certainly, 7-ketocholesterol is a major oxysterol found in cholesterol-rich processed foodstuffs. Dietary 7-ketocholesterol is rapidly metabolised by the liver to 7beta-hydroxycholesterol (cholest-5-ene-3beta,7beta-diol), unusual bile acids and perhaps even cholesterol itself. Its conversion to 7beta-hydroxycholesterol is well documented. (PMID: 15798369, 10224662). 7-Ketocholesterol is a major oxidation product of cholesterol (oxysterol) found in human atherosclerotic plaque and is more atherogenic than cholesterol in some animal studies. Oxysterols (oxygenated forms of cholesterol) are present at low levels in the circulation and accumulate is plasma and tissues in some pathologies. In atherosclerotic lesions, 7-oxygenated oxysterols, predominantly 7-ketocholesterol, accumulate and have been implicated in the pathology of the disease. There is some in vivo and in vitro evidence that sterol 27-hydroxylase acts on 7-ketocholesterol to initiate its degradation to more polar, water-soluble products. Recent studies indicate an alternative mechanism, in which 7-ketocholesterol is reduced to 7 beta-hydroxycholesterol by 11 beta-hydroxysteroid dehydrogenase type 1. 7-Ketocholesterol, toxic oxysterol, inhibits the rate-limiting step in bile acid biosynthesis cholesterol 7 alpha-hydroxylase, as well as strongly inhibiting HMG-CoA reductase (the rate-limiting enzyme in cholesterol biosynthesis). 7-Ketocholesterol induces cell apoptosis[1].
5-Methyl-2,4-bis(3-methyl-2-butenyl)-6-(2-methyl-1-oxopropyl)-5-(4-methyl-3-pentenyl)cyclohexanone
5-methyl-2,4-bis(3-methyl-2-butenyl)-6-(2-methyl-1-oxopropyl)-5-(4-methyl-3-pentenyl)cyclohexanone is found in alcoholic beverages. 5-methyl-2,4-bis(3-methyl-2-butenyl)-6-(2-methyl-1-oxopropyl)-5-(4-methyl-3-pentenyl)cyclohexanone is a constituent of Hypericum perforatum (St. Johns Wort) Constituent of Hypericum perforatum (St. Johns Wort). 5-methyl-2,4-bis(3-methyl-2-butenyl)-6-(2-methyl-1-oxopropyl)-5-(4-methyl-3-pentenyl)cyclohexanone is found in tea, alcoholic beverages, and herbs and spices.
MG(a-21:0/0:0/0:0)[rac]
MG(a-21:0/0:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(a-21:0/0:0/0:0) is made up of one 18-methyleicosanoyl(R1).
(3beta,5alpha,6a)-Cholesta-8,14-diene-3,6-diol
(3beta,5alpha,6a)-Cholesta-8,14-diene-3,6-diol is found in fruits. (3beta,5alpha,6a)-Cholesta-8,14-diene-3,6-diol is a constituent of Stenocereus thurberi (organ pipe cactus) Constituent of Stenocereus thurberi (organ pipe cactus). (3beta,5alpha,6a)-Cholesta-8,14-diene-3,6-diol is found in fruits.
5,6-trans-25-Hydroxyvitamin D3
5,6-trans-25-Hydroxyvitamin D3 is a vitamin D3 derivative, and is found in normal plasma. 5,6-trans-25-Hydroxyvitamin D3 is a 25-hydroxylated metabolite of the secosteroid that is active in inhibiting 3H-thymidine incorporation into cultured normal human keratinocytes. The evidence strongly supports the existence of a heretofore unknown metabolic route in vitamin DS metabolism, namely, the conversion of 5,6-cis compounds to 5,6-trans compounds. The mechanism of this transformation is not clear at present; it could be enzymatic or nonenzymatic. The site of formation of 5,6-trans-25-hydroxyvitamin D3 is unknown. (PMID 6256855, 10876100, 6270082) [HMDB] 5,6-trans-25-Hydroxyvitamin D3 is a vitamin D3 derivative, and is found in normal plasma. 5,6-trans-25-Hydroxyvitamin D3 is a 25-hydroxylated metabolite of the secosteroid that is active in inhibiting 3H-thymidine incorporation into cultured normal human keratinocytes. The evidence strongly supports the existence of a heretofore unknown metabolic route in vitamin DS metabolism, namely, the conversion of 5,6-cis compounds to 5,6-trans compounds. The mechanism of this transformation is not clear at present; it could be enzymatic or nonenzymatic. The site of formation of 5,6-trans-25-hydroxyvitamin D3 is unknown. (PMID 6256855, 10876100, 6270082).
25-Hydroxytachysterol3
25-Hydroxytachysterol3 is a hydroxylated derivative of tachysterol3. 25-hydroxytachysterol is converted to 25-hydroxyprevitamin D3, which is then converted to the hydroxyvitamin D3 through a thermally induced rearrangement. It is now established that, during exposure to sunlight, the cutaneous reservoir of 7-dehydrocholesterol converts to previtamin D3. Once this thermally labile previtamin is formed, it undergoes a temperature-dependent isomerization to vitamin D3 over a period of 3 days. The plasma vitamin-D binding protein preferentially translocates vitamin D3 from the skin into the circulation. During prolonged exposure to the sun, the accumulation of previtamin D3 is limited to about 10 to 15\\% of the original 7-dehydrocholesterol content because the previtamin photoisomerizes to 2 biologically inert photoproducts, lumisterol3 and tachysterol3. (PMID 12617640). 25-Hydroxytachysterol3 is characterized by antirachitic activity and by its ability to elevate serum calcium concentration in conditions of hypoparathyroidism. 25-Hydroxytachysterol3 can be used in the preparation of 25-hydroxydihydrotachysterol 3 (25-OH-DHT3) is considered an effective adjunct in the treatment of hypoparathyroidism, particularly where rapid action in elevating serum calcium concentration is being sought. (25-OH-DHT3) exhibits substantially greater antirachitic activity than DHT 3 [HMDB] 25-Hydroxytachysterol3 is a hydroxylated derivative of tachysterol3. 25-hydroxytachysterol is converted to 25-hydroxyprevitamin D3, which is then converted to the hydroxyvitamin D3 through a thermally induced rearrangement. It is now established that, during exposure to sunlight, the cutaneous reservoir of 7-dehydrocholesterol converts to previtamin D3. Once this thermally labile previtamin is formed, it undergoes a temperature-dependent isomerization to vitamin D3 over a period of 3 days. The plasma vitamin-D binding protein preferentially translocates vitamin D3 from the skin into the circulation. During prolonged exposure to the sun, the accumulation of previtamin D3 is limited to about 10 to 15\\% of the original 7-dehydrocholesterol content because the previtamin photoisomerizes to 2 biologically inert photoproducts, lumisterol3 and tachysterol3. (PMID 12617640). 25-Hydroxytachysterol3 is characterized by antirachitic activity and by its ability to elevate serum calcium concentration in conditions of hypoparathyroidism. 25-Hydroxytachysterol3 can be used in the preparation of 25-hydroxydihydrotachysterol 3 (25-OH-DHT3) is considered an effective adjunct in the treatment of hypoparathyroidism, particularly where rapid action in elevating serum calcium concentration is being sought. (25-OH-DHT3) exhibits substantially greater antirachitic activity than DHT 3.
Alfacalcidol
Alfacalcidol is an active metabolite of Vitamin D, which performs important functions in regulation of the calcium balance and the bone metabolism. Alfacalcidol is Vitamin D-hormone analog which is activated by the enzyme 25-hydroxylase in the liver for systemic and in osteoblasts for local D-hormone actions. It possesses a unique pattern of pleiotropic effects on, e.g. gut, bone, pararthyroids, muscle and brain. Alfacalcidol is superior to plain vitamin D (cholecalciferol) because the final kidney activation of the latter is regulated by a negative feedback mechanism. (PMID:17438884,17668216). A - Alimentary tract and metabolism > A11 - Vitamins > A11C - Vitamin a and d, incl. combinations of the two > A11CC - Vitamin d and analogues D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D050071 - Bone Density Conservation Agents
1-Phenyl-1,3-heneicosanedione
1-Phenyl-1,3-heneicosanedione is found in fats and oils. 1-Phenyl-1,3-heneicosanedione is a constituent of the pollen of Helianthus annuus (sunflower) Constituent of the pollen of Helianthus annuus (sunflower). 1-Phenyl-1,3-heneicosanedione is found in fats and oils.
5-(12,15-Heneicosadienyl)-1,3-benzenediol
5-(12,15-Heneicosadienyl)-1,3-benzenediol is found in cereals and cereal products. 5-(12,15-Heneicosadienyl)-1,3-benzenediol is a constituent of wheat and rye flour. Constituent of wheat and rye flour. 5-(12,15-Heneicosadienyl)-1,3-benzenediol is found in cereals and cereal products.
3-(Acetyloxy)-2-hydroxypropyl octadecanoate
3-(Acetyloxy)-2-hydroxypropyl octadecanoate belongs to the family of Alk(en)ylacylglycerols. These are Diradyclycerols characterized by one alk(en)yl chain and an acyl chain bound to a glycerol backbone.
3beta-Hydroxy-5-cholestenal
This compound belongs to the family of Monohydroxy Bile Acids, Alcohols and Derivatives. These are bile acids, alcohols or any of their derivatives bearing an hydroxyl group.
27alpha-Hydroxy-8-dehydrocholesterol
This compound belongs to the family of Dihydroxy Bile Acids, Alcohols and Derivatives. These are compounds containing or derived from a bile acid or alcohol, and which bears exactly two carboxylic acid groups.
MG(0:0/a-21:0/0:0)[rac]
MG(0:0/a-21:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/a-21:0/0:0) is made up of one 18-methyleicosanoyl(R2).
MG(0:0/21:0/0:0)
MG(0:0/21:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/21:0/0:0) is made up of one heneicosanoyl(R2).
MG(21:0/0:0/0:0)
MG(21:0/0:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(21:0/0:0/0:0) is made up of one heneicosanoyl(R1).
MG(0:0/i-21:0/0:0)
MG(0:0/i-21:0/0:0) belongs to the family of monoradyglycerols, which are glycerolipids lipids containing a common glycerol backbone to which at one fatty acyl group is attached. Their general formula is [R1]OCC(CO[R2])O[R3]. MG(0:0/i-21:0/0:0) is made up of one 19-methyleicosanoyl(R2).
DG(8:0/12:0/0:0)
DG(8:0/12:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/12:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/12:0)
DG(8:0/0:0/12:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/i-12:0/0:0)
DG(8:0/i-12:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/i-12:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/i-12:0)
DG(8:0/0:0/i-12:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(10:0/0:0/10:0)
DG(10:0/0:0/10:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(12:0/8:0/0:0)
DG(12:0/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(12:0/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(12:0/0:0/8:0)
DG(12:0/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-12:0/8:0/0:0)
DG(i-12:0/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-12:0/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-12:0/0:0/8:0)
DG(i-12:0/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
(1R,3Z)-3-[(2E)-2-[(1R,3As,7aR)-1-[(2R)-7-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
(1R)-3-[2-[(1R,3Ar,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
(1R)-5-[2-[(1R,7Ar)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(20S)-Hydroxyvitamin D3
Inecalcitol
22-Oxocholesterol
24,25-Epoxycholesterol
3-Hydroxycholest-5-en-7-one
3-Hydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,3,4,5,6,7,9,11,12,16,17-dodecahydrocyclopenta[a]phenanthren-15-one
Cholestane-2,3-dione
Prasterone enanthate
hydroxyvitamin d3
ketocholesterol
Sapogenins
Any of the aglycon moieties of saponins; they may be steroids or triterpenes. (ChEBI) Sapogenins are the aglycones, or non-saccharide, portions of the family of natural products known as saponins. Sapogenins contain steroid or other triterpene frameworks as their key organic feature. Sapogenins is found in soft-necked garlic. Any of the aglycon moieties of saponins; they may be steroids or triterpenes. (ChEBI)
13,16-Epoxy-25-hydroxy-17-cheilanthen-19,25-olide|Lintenolide C
(22E)-3beta,7alpha-dihydroxy-cholest-5,22-diene|(3beta,7alpha,22E)-Cholesta-5,22-diene-3,7-diol
Hyrtial
A scalarane sesterterpenoid with formula C26H40O3, originally isolated from the marine sponge Hyrtios erecta.
(3beta,5alpha,8alpha,22E)-5,8-Epidioxy-24-norcholesta-6,22-dien-3-ol
24-keto-cholesterol|24-Ketocholesterol|24-oxocholesterol|3beta-hydroxycholest-5-en-24-one|cholest-5-en-3beta-ol-24-one|ZK134306
24(R)-cholesta-5,25-diene-3beta,24-diol|cholesta-5,25-diene-3beta,24xi-diol|cholesta-5,25-diene-3beta-24-diol
3beta-Dimethylamino-20alpha(F)-methylacetamido-5-pregnen|saracocine|saracosine
4,8,13,17,21-pentamethyldocosa-4,8,12,16,20-pentaenoic acid
11-Cycloheptylundecanoic acid beta-oxophenethyl ester
3-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone|3alpha-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
25-hydroxy-4-cholesten-3-one|25-hydroxy-4-cholestene-3-one|25-Hydroxy-cholest-4-en-3-on|25-hydroxy-cholest-4-en-3-one|25-Hydroxycholest-4-en-3-one|ZK134308
4-(1-ethoxyethyl)-5-methyl-2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzene-1,3-diol
(1R,2aR,6aS,7R,9aR,10aS,10bR)-7-[(1S,2Z)-1,5-dimethylhexa-2,4-dien-1-yl]-2,2a,4,6,6a,7,8,9,9a,10,10a,10b-dodecahydro-2a-methoxy-1,9a-dimethyl-1H-3-oxacyclopenta[5,6]cycloocta[1,2,3-cd]pentalen-1-ol|(5alpha,6alpha)-5-O-methylophiobolin H
3-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
A tetracyclic triterpenoid found in Dysoxylum lenticellatum.
24,25,26,27-tetranor-3-oxo-9BetaH-lanosta-7-en-23-oic acid
6beta-Hydroxy-cholest-4-en-3-on|6beta-hydroxy-cholest-4-en-3-one|6beta-hydroxycholest-4-en-3-one|cholest-4-en-6beta-ol-3-one
(20R)-3beta-Hydroxy-24,25,26,27-tetranor-5alpha-cycloartan-23,21-olide|3beta-3-Hydroxy-24,25,26,27-tetranorcycloartan-23,21-olide
25,26,27-trisnor-3beta-hydroxy-cycloartan-24-al|25,26,27-trisnor-3beta-hydroxycycloartan-24-al|wrightial
(3beta, 5alpha, 7alpha, 22E)-Cholesta-8(14), 22-diene-3, 7-diol
plakortone L
An organic heterobicyclic compound consisting of a gamma-lactone ring fused onto a substituted tetrahydrofuran ring. It is isolated from the Australian marine sponge Plakinastrella clathrata.
12beta-12-Hydroxy-24-methyl-24-oxo-16-scalaren-25-al-
MLS001333092-01!5-Cholesten-3beta-ol-7-one566-28-9
7-KETOCHOLESTEROL
A cholestanoid that consists of cholesterol bearing an oxo substituent at position 7. D004791 - Enzyme Inhibitors 7-Ketocholesterol, toxic oxysterol, inhibits the rate-limiting step in bile acid biosynthesis cholesterol 7 alpha-hydroxylase, as well as strongly inhibiting HMG-CoA reductase (the rate-limiting enzyme in cholesterol biosynthesis). 7-Ketocholesterol induces cell apoptosis[1].
Ala Ile Val Val
Ala Leu Val Val
Ala Val Ile Val
Ala Val Leu Val
Ala Val Val Ile
Ala Val Val Leu
Gly Ile Ile Val
Gly Ile Leu Val
Gly Ile Val Ile
Gly Ile Val Leu
Gly Leu Ile Val
Gly Leu Leu Val
Gly Leu Val Ile
Gly Leu Val Leu
Gly Val Ile Ile
Gly Val Ile Leu
Gly Val Leu Ile
Gly Val Leu Leu
Ile Ala Val Val
Ile Gly Ile Val
Ile Gly Leu Val
Ile Gly Val Ile
Ile Gly Val Leu
Ile Ile Gly Val
Ile Ile Val Gly
Ile Leu Gly Val
Ile Leu Val Gly
Ile Val Ala Val
Ile Val Gly Ile
Ile Val Gly Leu
Ile Val Ile Gly
Ile Val Leu Gly
Ile Val Val Ala
Leu Ala Val Val
Leu Gly Ile Val
Leu Gly Leu Val
Calcifediol
A - Alimentary tract and metabolism > A11 - Vitamins > A11C - Vitamin a and d, incl. combinations of the two > A11CC - Vitamin d and analogues H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D050071 - Bone Density Conservation Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(5Z,7E,17E)-(1S,3R)-21-nor-9,10-seco-5,7,10(19),17-cholestatetraene-1,3,25-triol
(5Z,7E,17Z)-(1S,3R)-21-nor-9,10-seco-5,7,10(19),17-cholestatetraene-1,3,25-triol
1α-hydroxyvitamin D3 / 1α-hydroxycholecalciferol
1α-hydroxy-3-epivitamin D3 / 1α-hydroxy-3-epicholecalciferol
(5E)-1α-hydroxyvitamin D3 / (5E)-1α-hydroxycholecalciferol
(5E,7E)-(1S,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
1β-hydroxyvitamin D3 / 1β-hydroxycholecalciferol
1β-hydroxy-3-epivitamin D3 / 1β-hydroxy-3-epicholecalciferol
(5E)-1β-hydroxyvitamin D3 / (5E)-1β-hydroxycholecalciferol
(5E,7E)-(1R,3S)-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
2β-hydroxyvitamin D3 / 2β-hydroxycholecalciferol
1α,25-dihydroxy-3-deoxyvitamin D3 / 1α,25-dihydroxy-3-deoxycholecalciferol
(22S)-22-hydroxyvitamin D3 / (22S)-22-hydroxycholecalciferol
(24R)-24-hydroxyvitamin D3 / (24R)-24-hydroxycholecalciferol
(24S)-24-hydroxyvitamin D3 / (24S)-24-hydroxycholecalciferol
25-hydroxy-14-epivitamin D3 / 25-hydroxy-14-epicholecalciferol
19-Nor-14,20-bisepi-23-yne-1,25 dihydroxyvitamin D3
19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3
5,6-trans-25-Hydroxyvitamin D3
22-Hydroxyvitamin D3
D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
Alfacalcidol
A - Alimentary tract and metabolism > A11 - Vitamins > A11C - Vitamin a and d, incl. combinations of the two > A11CC - Vitamin d and analogues D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D050071 - Bone Density Conservation Agents
DHEA ENANTHATE
Thurberol
5-Methyl-2,4-bis(3-methyl-2-butenyl)-6-(2-methyl-1-oxopropyl)-5-(4-methyl-3-pentenyl)cyclohexanone
ascr#27
An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,15R)-15-hydroxyhexadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
oscr#27
An omega-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E)-16-hydroxyhexadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
ST 26:3;O3
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D000728 - Androgens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
1alpha-hydroxyvitamin D3 / 1alpha-hydroxycholecalciferol
1alpha-hydroxy-3-epivitamin D3 / 1alpha-hydroxy-3-epicholecalciferol
(5E)-1alpha-hydroxyvitamin D3 / (5E)-1alpha-hydroxycholecalciferol
(5E)-1alpha-hydroxy-3-epivitamin D3 / (5E)-1alpha-hydroxy-3-epicholecalciferol
1beta-hydroxyvitamin D3 / 1beta-hydroxycholecalciferol
1beta-hydroxy-3-epivitamin D3 / 1beta-hydroxy-3-epicholecalciferol
(5E)-1beta-hydroxyvitamin D3 / (5E)-1beta-hydroxycholecalciferol
(5E)-1beta-hydroxy-3-epivitamin D3 / (5E)-1beta-hydroxy-3-epicholecalciferol
2alpha-hydroxyvitamin D3 / 2alpha-hydroxycholecalciferol
2beta-hydroxyvitamin D3 / 2beta-hydroxycholecalciferol
1alpha,25-dihydroxy-3-deoxyvitamin D3 / 1alpha,25-dihydroxy-3-deoxycholecalciferol
calcidiol
A hydroxycalciol that is calciol in which the hydrogen at position 25 has been replaced by a hydroxy group. A prehormone resulting from the oxidation of calciol in the liver, it is further hydroxylated in the kidney to give calcitriol, the active form of vitamin D3.
Inecalcitol
Dedrogyl
A - Alimentary tract and metabolism > A11 - Vitamins > A11C - Vitamin a and d, incl. combinations of the two > A11CC - Vitamin d and analogues H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D050071 - Bone Density Conservation Agents
1,7-bis-(tert-Butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane
C20H40N4O4 (400.30494000000004)
17-(1-methoxycyclohexyl)oxy-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
Colestolone
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent D009676 - Noxae > D000963 - Antimetabolites
tert-butyl 4-(2-oxo-3,3-dipropylindol-1-yl)piperidine-1-carboxylate
1,3-Propanediyl-bis(tripropylphosphonium) difluoride solution
C21H48F2P2 (400.3199131999999)
3-Hydroxy-2,2-bis(hydroxymethyl)propyl 9-octadecenoate
(2E)-16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]hexadec-2-enoic acid
(2E,15R)-15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]hexadec-2-enoic acid
(17E)-1alpha,25-dihydroxy-17,20-didehydro-21-norvitamin D3/(17E)-1alpha,25-dihydroxy-17,20-didehydro-21-norcholecalciferol
(22S)-22-hydroxyvitamin D3/(22S)-22-hydroxycholecalciferol
25-Hydroxycholest-4-en-3-one
A cholestanoid that is cholest-4-en-3-one which carries a hydroxy group at position 25.
(25R)-3beta-hydroxycholest-5-en-26-al
A 3beta-hydroxycholest-5-en-26-al in which the stereocentre at position 25 has R-configuration.
(4E)-4-[(2Z)-2-(5-hydroxy-2-methylidenecyclohexylidene)ethylidene]-7a-methyl-1-(6-methylheptan-2-yl)-2,3,3a,5,6,7-hexahydro-1H-inden-2-ol
[(S)-3-Carboxylato-2-(palmitoyloxy)propyl]trimethylaminium
C23H46NO4+ (400.34266560000003)
[3-carboxy-2-[(Z)-13-carboxytridec-5-enoyl]oxypropyl]-trimethylazanium
[3-Carboxy-2-(14-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(12-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(9-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(5-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(6-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(11-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(3-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(8-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(7-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(13-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-Carboxy-2-(4-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
[3-carboxy-2-[(E)-13-carboxytridec-7-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxytridec-2-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxytridec-4-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxytridec-5-enoyl]oxypropyl]-trimethylazanium
[3-Carboxy-2-(10-methylpentadecanoyloxy)propyl]-trimethylazanium
C23H46NO4+ (400.34266560000003)
(3Z)-3-[(2E)-2-[1-(7-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
(3Z)-3-[(2E)-2-[1-(2-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
(20S)-Hydroxyvitamin D3
A hydroxycalciol that consists of vitamin D3 (calciol) carrying an additional hydroxy group at position 20 with S-configuration. D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
3beta-Hydroxycholest-5-en-26-al
A 26-oxo steroid resulting from the oxidation of one of the terminal methyl groups of cholesterol to the corresponding aldehyde.
(3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-7-one
(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid
2-[(3S)-3-acetyloxyhexadecanoyl]oxyethyl-trimethylazanium
C23H46NO4+ (400.34266560000003)
(1-Hexanoyloxy-3-hydroxypropan-2-yl) tetradecanoate
2-(Trimethylsilyloxy)nonadecanoic acid methyl ester
C23H48O3Si (400.3372537999999)
1,1-Bis(tert-butyldimethylsilyl)-2,2-bis(trimethylsilyl)ethylene
C20H48Si4 (400.28329279999997)
Ethyl (4AS,5S,8AS)-E-(+)-3-methyl-5-((5alpha-(4-methyl-3-pentenyl)-2,5beta,8abeta-trimethyl-3,4,4A,5,6,7,8,8A-octahydronaphthalenyl)-2-pentenoate
(1-Hydroxy-3-propanoyloxypropan-2-yl) heptadecanoate
(1-Heptanoyloxy-3-hydroxypropan-2-yl) tridecanoate
(1-Hydroxy-3-pentanoyloxypropan-2-yl) pentadecanoate
Testosterone Enanthate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D000728 - Androgens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
(4E,6E,8E,10E,12E,14E,16E,18E,20E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaene
(3beta,5E,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
cholesta-5,7-dien-3beta,25-diol
A cholestanoid that is 7-dehydrocholesterol carrying an additional hydroxy substituent at position 25.
(24Z),26-hydroxydesmosterol
A cholestanoid that is desmosterol carrying an additional hydroxy susbstituent at position 26.
cholesta-5,7-dien-3beta,24S-diol
A cholestanoid that is 7-dehydrocholesterol carrying an additional hydroxy substituent at position 24 (24S-stereoisomer).
7alpha-Hydroxycholest-4-en-3-one
A cholestanoid consisting of a cholesterol core having an oxo group at the 3-position, a C=C bond at the 4,5-position and an alpha-hydroxy group at the 7-position.
WE(27:5)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1r,3ar,3bs,5r,9ar,9bs,11ar)-1-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-5-hydroxy-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
(4e,8e,12e,16e)-4,8,13,17,21-pentamethyldocosa-4,8,12,16,20-pentaenoic acid
(1s)-3-{2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-hexahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
(1r,3as,3bs,7s,9ar,9bs,11ar)-1-[(2r,5s)-5-hydroxy-6-methylhept-6-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol
(2s)-2,8-dimethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]chromen-6-ol
(1r,3as,3bs,7s,9ar,9bs,11ar)-1-[(2r,5r)-5-hydroxy-6-methylhept-6-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol
16-(1-aminoethyl)-6-(dimethylamino)-7,7,13,18-tetramethyltetracyclo[9.7.0.0³,⁸.0¹³,¹⁷]octadeca-1,3-dien-15-ol
1-(5-ethyl-6-methylheptan-2-yl)-7-hydroxy-1h,2h,3h,3ah,3bh,6h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-4-one
n-[(1s)-1-[(1s,3as,3bs,7r,9ar,9bs,11as)-7-(dimethylamino)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-n-methylacetamide
15-hydroxy-n-[2-(1h-indol-3-yl)ethyl]pentadecanimidic acid
2-methyl-6-[(2e,7r,11r)-3,7,11,15-tetramethylhexadec-2-en-1-yl]cyclohexa-2,5-diene-1,4-dione
(1r,3as,3bs,7s,9ar,9bs,11ar)-1-[(2r,4e)-6-hydroxy-6-methylhept-4-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol
n-[(1r)-1-[(1r,3ar,3br,7s,9as,9br,11as)-7-(dimethylamino)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-n-methylacetamide
(2r,3r,4s,6s)-3-methyl-4,6-di(3-methyl-2-butenyl)-2-(2-methyl-1-oxopropyl)-3-(4-meth-yl-3-pentenyl)-cyclohexanone
{"Ingredient_id": "HBIN006443","Ingredient_name": "(2r,3r,4s,6s)-3-methyl-4,6-di(3-methyl-2-butenyl)-2-(2-methyl-1-oxopropyl)-3-(4-meth-yl-3-pentenyl)-cyclohexanone","Alias": "NA","Ingredient_formula": "C27H44O2","Ingredient_Smile": "CC(C)C(=O)C1C(=O)C(CC(C1(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "14315","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
abricin
{"Ingredient_id": "HBIN014233","Ingredient_name": "abricin","Alias": "NA","Ingredient_formula": "C27H44O2","Ingredient_Smile": "NA","Ingredient_weight": "400.64","OB_score": "40.7324","CAS_id": "73030-55-4","SymMap_id": "SMIT09065","TCMID_id": "NA","TCMSP_id": "MOL007682","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1s,3r,6s,8r,11s,12r,14r,15s,16r)-6-(dimethylamino)-12,16-dimethyl-15-[(1s)-1-(methylamino)ethyl]-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-ol
9-methoxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-10-en-15-ol
(5s)-5-[(1s,3ar,3br,5as,9as,9br,11ar)-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5-methyloxolan-2-one
(1r,3ar,5as,7s,9ar,9br,11ar)-7-hydroxy-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-1h,2h,3h,3ah,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one
(4as,4br,6r,6ar,10as,10br,12as)-8-formyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate
1-[4-(3,3-dimethyloxiran-2-yl)butan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol
(1s,3r,6r,7s,9e,13r,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol
(3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-3a,5a,5b,8,8,11a-hexamethyl-tetradecahydro-2h-cyclopenta[a]chrysen-1-one
2,8-dimethyl-2-(4,8,12-trimethyltridec-11-en-1-yl)-3,4-dihydro-1-benzopyran-6-ol
6-(dimethylamino)-12,16-dimethyl-15-[1-(methylamino)ethyl]-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-ol
1-(6-hydroxy-6-methylhept-4-en-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-ol
(2-{[(3s)-3-(acetyloxy)hexadecanoyl]oxy}ethyl)trimethylazanium
[C23H46NO4]+ (400.34266560000003)